These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16322682)

  • 1. Intralesional targeted alpha therapy for metastatic melanoma.
    Allen BJ; Raja C; Rizvi S; Li Y; Tsui W; Graham P; Thompson JF; Reisfeld RA; Kearsley J
    Cancer Biol Ther; 2005 Dec; 4(12):1318-24. PubMed ID: 16322682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted alpha therapy for cancer.
    Allen BJ; Raja C; Rizvi S; Li Y; Tsui W; Zhang D; Song E; Qu CF; Kearsley J; Graham P; Thompson J
    Phys Med Biol; 2004 Aug; 49(16):3703-12. PubMed ID: 15446799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical targeted alpha therapy for subcutaneous melanoma.
    Allen BJ; Rizvi SM; Tian Z
    Melanoma Res; 2001 Apr; 11(2):175-82. PubMed ID: 11333128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro targeting of NG2 antigen by 213Bi-9.2.27 alpha-immunoconjugate induces cytotoxicity in human uveal melanoma cells.
    Li Y; Wang J; Rizvi SM; Jager MJ; Conway RM; Billson FA; Allen BJ; Madigan MC
    Invest Ophthalmol Vis Sci; 2005 Dec; 46(12):4365-71. PubMed ID: 16303921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma.
    Allen BJ; Singla AA; Rizvi SM; Graham P; Bruchertseifer F; Apostolidis C; Morgenstern A
    Immunotherapy; 2011 Sep; 3(9):1041-50. PubMed ID: 21913827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers.
    Allen BJ; Rizvi S; Li Y; Tian Z; Ranson M
    Crit Rev Oncol Hematol; 2001; 39(1-2):139-46. PubMed ID: 11418311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo studies of pharmacokinetics and efficacy of Bismuth-213 labeled antimelanoma monoclonal antibody 9.2.27.
    Rizvi SM; Qu CF; Song YJ; Raja C; Allen BJ
    Cancer Biol Ther; 2005 Jul; 4(7):763-8. PubMed ID: 15970703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer.
    Allen BJ; Raja C; Rizvi S; Song EY; Graham P
    Phys Med Biol; 2007 Jul; 52(13):L15-9. PubMed ID: 17664565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
    Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ
    Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunoconjugates for targeted alpha therapy of malignant melanoma.
    Abbas Rizvi SM; Sarkar S; Goozee G; Allen BJ
    Melanoma Res; 2000 Jun; 10(3):281-9. PubMed ID: 10890383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radionuclide antibody-conjugates, a targeted therapy towards cancer.
    Kitson SL; Cuccurullo V; Moody TS; Mansi L
    Curr Radiopharm; 2013 Jun; 6(2):57-71. PubMed ID: 23808764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma.
    Bosserhoff AK; Dreau D; Hein R; Landthaler M; Holder WD; Buettner R
    Recent Results Cancer Res; 2001; 158():158-68. PubMed ID: 11092043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study.
    Danielli R; Patuzzo R; Di Giacomo AM; Gallino G; Maurichi A; Di Florio A; Cutaia O; Lazzeri A; Fazio C; Miracco C; Giovannoni L; Elia G; Neri D; Maio M; Santinami M
    Cancer Immunol Immunother; 2015 Aug; 64(8):999-1009. PubMed ID: 25971540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma.
    Raja C; Graham P; Abbas Rizvi SM; Song E; Goldsmith H; Thompson J; Bosserhoff A; Morgenstern A; Apostolidis C; Kearsley J; Reisfeld R; Allen BJ
    Cancer Biol Ther; 2007 Jun; 6(6):846-52. PubMed ID: 17495524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of targeted alpha therapy with
    Królicki L; Bruchertseifer F; Kunikowska J; Koziara H; Królicki B; Jakuciński M; Pawlak D; Apostolidis C; Mirzadeh S; Rola R; Merlo A; Morgenstern A
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):614-622. PubMed ID: 30498897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.
    Weide B; Eigentler TK; Pflugfelder A; Zelba H; Martens A; Pawelec G; Giovannoni L; Ruffini PA; Elia G; Neri D; Gutzmer R; Becker JC; Garbe C
    Cancer Immunol Res; 2014 Jul; 2(7):668-78. PubMed ID: 24906352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phototherapy-induced elevation of serum level of melanoma inhibitory activity.
    Datz E; Zeman F; Koller M; Szeimies RM; Berneburg M; Landthaler M; Bosserhoff AK; Karrer S
    Photodermatol Photoimmunol Photomed; 2019 Jul; 35(4):255-260. PubMed ID: 30815924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF.
    Si Z; Hersey P; Coates AS
    Melanoma Res; 1996 Jun; 6(3):247-55. PubMed ID: 8819128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Melanoma inhibitory activity" (MIA): a promising serological tumour marker in metastatic uveal melanoma.
    Reiniger IW; Schaller UC; Haritoglou C; Hein R; Bosserhoff AK; Kampik A; Mueller AJ
    Graefes Arch Clin Exp Ophthalmol; 2005 Nov; 243(11):1161-6. PubMed ID: 15906071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.